By The Independent Staff
A bi-partisan bi-cameral group of legislators introduced legislation Jan. 30 that would establish a program to allow New Mexicans to receive medical treatments from psilocybin mushrooms for qualified medical conditions.
According to a press release, Senate Bill 219, the “Medical Psilocybin Act” lays the path for mental and behavioral health treatment for New Mexicans suffering from major treatment-resistant depression, post-traumatic stress disorder, substance use disorders, end-of-life care and other conditions approved by the Department of Health.
“Research shows that psilocybin used in coordination with a licensed therapist has positive effects on people with depression and PTSD by reducing fear and anxiety, disrupting negative thought loops, and leading to long-term symptom relief in short periods,” Rep. Stefani Lord (R-Sandia Park) said. “We owe it to New Mexicans to explore the therapeutic potential of psilocybin.”
The act establishes a Medical Psilocybin Advisory Board to advise on the safe administration of psilocybin in approved settings. It includes a Medical Psilocybin Treatment Equity Fund to provide fair access and a Medical Psilocybin Research Fund to advance knowledge. The act also amends the Controlled Substances Act to remove psilocybin and psilocin from the schedule for purposes of qualified and registered patients, clinicians and producers, thus providing legal protection under the program.
“I’m excited to be able to offer this breakthrough medical treatment to New Mexicans,” Sen. Craig Brandt (R-Rio Rancho) said. “Medical psilocybin is proving to be effective in treating traumatic brain injuries, post-traumatic stress disorder (PTSD), depression, and other mental health conditions. As a veteran I’m hopeful that this new medical option will provide help to my fellow veterans.”
The Medical Psilocybin Program would be available for New Mexicans by December 31, 2027, following a necessary rule-making process by the Department of Health.
“When we’re facing epidemic levels of depression, anxiety, PTSD, and other debilitating mental health conditions, we owe it to those suffering to explore promising new treatments like psilocybin,” Rep. Liz Thomson (D-Albuquerque) said. “By establishing a highly-regulated, state-run program, we can provide alternative options to those not responding to traditional treatment in a safe, controlled environment.”